Broadcast Date: 
  • Time: 

Advanced therapy products are demonstrating continued success. A steady increase in the number of products moving into late-phase clinical studies and the potential to include more common disease indications with much higher patient numbers has led to increased demand for plasmid DNA supply and greater pressure on worldwide manufacturing capacity.

This GEN webinar will explore developments within Charles River’s plasmid DNA CDMO service offerings, including platform screening and manufacturing approaches, improved supply chain management, 100% in-house testing, and, most recently, the launch of off-the-shelf plasmid products for viral vector manufacture.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

charles river logo

Andrew Frazer
Andrew Frazer, PhD
Associate Director, Scientific Solutions, Gene Therapy
Charles River Laboratories